Interstitial lung disease in connective tissue disorders.
Some of the most pressing challenges associated with interstitial lung disease (ILD) are how best to define, diagnose, and treat connective tissue disease-associated ILD (CTD-ILD)--disorders with potentially substantial morbidity and mortality. In this focused review, we address aspects of prognosis for CTD-ILD and what indices might predict outcome, together with lessons that can be learnt from clinical trials of systemic sclerosis-associated ILD and idiopathic pulmonary fibrosis and how these lessons might be applied to future studies of CTD-ILD.
Division of Rheumatology and Interstitial Lung Disease Program, National Jewish Health, Denver, CO, USA.
Aryeh
A
Fischer
Roland
R
du Bois
D003240:Connective Tissue Diseases / Q000150:complications*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D017563:Lung Diseases, Interstitial / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D011379:Prognosis; D012595:Scleroderma, Systemic / Q000150:complications; D016896:Treatment Outcome
D007166:Immunosuppressive Agents